Brivaracetam

Drug Profile

Brivaracetam

Alternative Names: BRIVIACT; BRIVLERA; RIKELTA; UCB-34714

Latest Information Update: 18 Jan 2017

Price : $50

At a glance

  • Originator UCB
  • Class Antiepileptic drugs; Neuroprotectants; Non-opioid analgesics; Nootropics; Pyrrolidinones; Small molecules
  • Mechanism of Action Sodium channel antagonists; SV2A protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myoclonic epilepsies
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Epilepsy
  • Discontinued Myoclonic epilepsies; Postherpetic neuralgia

Most Recent Events

  • 11 Jan 2017 UCB Biopharma plans a phase II trial for Epilepsy in USA (IV) (NCT03021018)
  • 31 May 2016 Launched for Epilepsy (Adjunctive treatment) in Denmark (PO), (IV)
  • 31 May 2016 Launched for Epilepsy (Adjunctive treatment) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top